TCS, Wipro harnesses AI capabilities in fight against covid-19

Mumbai: Several Indian technology companies with extensive investments in areas of digital growth are actively harnessing analytics and artificial intelligence (AI) to simulate drug trials, which in normal course takes years.

From virtualised production of advanced drug molecules to applying data analytics for quick contact tracing, several Indian tech companies have deployed AI in the forefront of fight against covid-19. For instance, Tata Consultancy Services (TCS), India’s largest IT and software services provider, has shortlisted 31 new drug-like molecules which are now being tested in further trials as a potential cure for the pandemic.

“We knew that SARS-CoV-2 virus which is responsible for the disease produces a protein that undergoes viral replication,” said Gopalkrishnan Bulusu, principal scientist, TCS Innovation Labs.